Sage Therapeutics shares surged 45% in premarket trade Tuesday, after the company reported positive results from a trial of a drug to treat severe postpartum depression. The company said a Phase 2 trial of SAGE-547 met its primary endpoint of a significant reduction in symptoms compared to placebo at 60 hours. “This is potentially one of the most important clinical findings in the pharmacologic treatment of postpartum depression to date,” said Samantha Meltzer-Brody, M.D., M.P.H., associate professor and director of the UNC Perinatal Psychiatry Program of the UNC Center for Women’s Mood Disorders and primary investigator for the PPD-202 Trial. There are currently no approved treatments specifically developed for postpartum depression, which affects 10% to 15% of mothers and can have devastating consequences.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News